Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 4
2003 9
2004 3
2005 3
2006 2
2007 2
2008 4
2009 1
2010 3
2011 3
2012 3
2013 5
2014 3
2015 4
2016 6
2017 3
2019 1
2020 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
Chavanet P. Chavanet P. Med Mal Infect. 2013 Dec;43(11-12):451-5. doi: 10.1016/j.medmal.2013.09.011. Epub 2013 Nov 13. Med Mal Infect. 2013. PMID: 24238896 Clinical Trial.
The current guidelines for the treatment of MRSA nosocomial pneumonia include vancomycin and linezolid. The authors of 2 prospective randomized trials comparing vancomycin and linezolid in nosocomial pneumonia had concluded to the non-inferiority of …
The current guidelines for the treatment of MRSA nosocomial pneumonia include vancomycin and linezolid. The authors of 2 prosp …
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Wunderink RG, et al. Clin Infect Dis. 2012 Mar 1;54(5):621-9. doi: 10.1093/cid/cir895. Epub 2012 Jan 12. Clin Infect Dis. 2012. PMID: 22247123 Clinical Trial.
RESULTS: Of 1184 patients treated, 448 (linezolid, n = 224; vancomycin, n = 224) were included in the mITT and 348 (linezolid, n = 172; vancomycin, n = 176) in the PP population. ...All-cause 60-day mortality was similar (linezolid, 15.7%; va …
RESULTS: Of 1184 patients treated, 448 (linezolid, n = 224; vancomycin, n = 224) were included in the mITT and 348 (linezol …
Randomized Controlled Trial to Determine the Efficacy of Early Switch From Vancomycin to Vancomycin Alternatives as a Strategy to Prevent Nephrotoxicity in Patients With Multiple Risk Factors for Adverse Renal Outcomes (STOP-NT).
Carreno JJ, Kenney RM, Divine G, Vazquez JA, Davis SL. Carreno JJ, et al. Ann Pharmacother. 2017 Mar;51(3):185-193. doi: 10.1177/1060028016673858. Epub 2016 Nov 13. Ann Pharmacother. 2017. PMID: 27838680 Clinical Trial.
Patients initially prescribed vancomycin between October 2011 to April 2013 with at least 2 risk factors for AKI were included. ...The incidence of AKI was 32.7% in the alternative therapy group and 31.4% in the vancomycin group ( P = 0.89). CONCLUSIONS: No signific …
Patients initially prescribed vancomycin between October 2011 to April 2013 with at least 2 risk factors for AKI were included. ...Th …
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Jaksic B, et al. Clin Infect Dis. 2006 Mar 1;42(5):597-607. doi: 10.1086/500139. Epub 2006 Jan 25. Clin Infect Dis. 2006. PMID: 16447103 Clinical Trial.
METHODS: To compare the safety and efficacy of linezolid and vancomycin in febrile, neutropenic patients with cancer, we conducted a double-blind, multicenter equivalence study. ...CONCLUSIONS: Linezolid demonstrated efficacy and similar safety outcomes equiv …
METHODS: To compare the safety and efficacy of linezolid and vancomycin in febrile, neutropenic patients with cancer, we condu …
Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
Niederman MS, Chastre J, Solem CT, Wan Y, Gao X, Myers DE, Haider S, Li JZ, Stephens JM. Niederman MS, et al. Clin Ther. 2014 Sep 1;36(9):1233-1243.e1. doi: 10.1016/j.clinthera.2014.06.029. Epub 2014 Jul 25. Clin Ther. 2014. PMID: 25066668 Clinical Trial.
A piggyback cost-effectiveness analysis was conducted to assess the incremental cost-effectiveness ratio of linezolid versus vancomycin, given the significantly higher clinical success of linezolid compared with vancomycin found in the trial. FINDINGS: …
A piggyback cost-effectiveness analysis was conducted to assess the incremental cost-effectiveness ratio of linezolid versus vanco …
A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.
Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, Cammarata SK, Pullman J. Kingsley J, et al. J Antimicrob Chemother. 2016 Mar;71(3):821-9. doi: 10.1093/jac/dkv411. Epub 2015 Dec 17. J Antimicrob Chemother. 2016. PMID: 26679243 Free PMC article. Clinical Trial.
METHODS: In a double-blind, Phase 2 trial, 256 patients were randomized (1 : 1 : 1) to 300 mg of delafloxacin, 600 mg of linezolid or 15 mg/kg vancomycin (actual body weight), each administered intravenously twice daily for 5-14 days. ...Cure rates with delafloxacin …
METHODS: In a double-blind, Phase 2 trial, 256 patients were randomized (1 : 1 : 1) to 300 mg of delafloxacin, 600 mg of linezolid or …
Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study.
Wan Y, Li Q, Chen Y, Haider S, Liu S, Gao X. Wan Y, et al. J Med Econ. 2016;19(1):53-62. doi: 10.3111/13696998.2015.1088448. Epub 2015 Oct 22. J Med Econ. 2016. PMID: 26490296 Free article. Clinical Trial.
Impact of renal failure was assessed using regression model. RESULTS: Data from 448 patients (1:1 linezolid:vancomycin) were analyzed. More patients treated with linezolid achieved success (55% [95% CI = 48-62%]) than with vancomycin (45% [38-52%]). .. …
Impact of renal failure was assessed using regression model. RESULTS: Data from 448 patients (1:1 linezolid:vancomycin) were a …
Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
Patanwala AE, Erstad BL, Nix DE. Patanwala AE, et al. Curr Med Res Opin. 2007 Jan;23(1):185-93. doi: 10.1185/030079906X162700. Curr Med Res Opin. 2007. PMID: 17257479 Clinical Trial.
Three clinical scenarios were considered in the decision analysis: (1) treatment with intravenous (IV) vancomycin during hospitalization and after discharge with home-care follow-up; (2) treatment with IV vancomycin during hospitalization, followed by oral linezo …
Three clinical scenarios were considered in the decision analysis: (1) treatment with intravenous (IV) vancomycin during hospitalizat …
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Li JZ, et al. Surg Infect (Larchmt). 2003 Spring;4(1):57-70. doi: 10.1089/109629603764655290. Surg Infect (Larchmt). 2003. PMID: 12744768 Clinical Trial.
MATERIALS AND METHODS: Patients received up to four weeks of linezolid (intravenous followed by optional oral) or vancomycin (intravenous only), followed by up to four weeks of observation. ...RESULTS: The unadjusted Kaplan-Meier median LOS was five days shorter for …
MATERIALS AND METHODS: Patients received up to four weeks of linezolid (intravenous followed by optional oral) or vancomycin ( …
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.
Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C; Linezolid CSSTI Study Group. Weigelt J, et al. Antimicrob Agents Chemother. 2005 Jun;49(6):2260-6. doi: 10.1128/AAC.49.6.2260-2266.2005. Antimicrob Agents Chemother. 2005. PMID: 15917519 Free PMC article. Clinical Trial.
Patients were randomized (1:1) to receive linezolid (600 mg) every 12 h either intravenously (i.v.) or orally or vancomycin (1 g) every 12 h i.v. ...Drug-related adverse events were reported in similar numbers in both the linezolid and the vancomycin a …
Patients were randomized (1:1) to receive linezolid (600 mg) every 12 h either intravenously (i.v.) or orally or vancomycin (1 …
56 results